Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 9/20 | 0.43 |
| ▸ | CA2 | P00918 | 9/20 | 0.43 |
| ▸ | CA9 | Q16790 | 7/20 | 0.43 |
| ▸ | CA12 | O43570 | 6/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.40 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.40 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17973933 | 0.85 | KMT2A (0.39) | CA1CA2CA9CA12MEN1 | |
| SCHEMBL19966589 | 0.84 | CA12 (0.43) | CA1CA2CA9CA12MMP1 | |
| SCHEMBL31504508 | 0.82 | ALOX5 (0.51) | CA1CA2CA9CA12KMT2A | |
| SCHEMBL973720 | 0.80 | CA1 (0.47) | CA1CA2CA9CA12MEN1 | |
| SCHEMBL4951056 | 0.79 | ALDH1A1 (0.54) | CA1CA2CA9CA12MEN1 | |
| SCHEMBL9632713 | 0.79 | MEN1 (0.44) | CA1CA2CA9CA12MEN1 | |
| SCHEMBL16897446 | 0.78 | PKM (0.50) | CA1CA2CA9CA12MEN1 | |
| SCHEMBL11794766 | 0.78 | F2 (0.49) | CA1CA2CA9CA12MEN1 | |
| SCHEMBL497667 | 0.78 | NFKB1 (0.53) | CA1CA2MEN1KMT2AMMP1 | |
| SCHEMBL31529428 | 0.77 | LMNA (0.42) | CA1CA2CA9CA12KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250334596-A1 | ISOTOPIC LABELS FOR QUANTITATIVE MASS SPECTROMETRY OF LIPID ISOMERS | TEXAS A & M UNIV SYS (US) | 2025-10-30 | — | — | US | claimed |
| CN-119059990-B | Preparation method of 1-carbamic acid tert-butyl piperazine | 安徽昊帆生物有限公司 | 2025-02-07 | — | — | CN | claimed |
| CN-119059990-A | Preparation method of 1-carbamic acid tert-butyl piperazine | 安徽昊帆生物有限公司 | 2024-12-03 | — | — | CN | claimed |
| CN-114478303-A | Method for synthesizing carbidopa | 浙江野风药业股份有限公司 | 2022-05-13 | — | — | CN | claimed |
| US-20260102387-A1 | IMMUNOSUPPRESSIVE COMPOUNDS | UNIV BASEL (CH) | 2026-04-16 | — | — | US | disclosed |
| US-20250334596-A1 | ISOTOPIC LABELS FOR QUANTITATIVE MASS SPECTROMETRY OF LIPID ISOMERS | TEXAS A & M UNIV SYS (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250257060-A1 | OXADIAZOLE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | SUZHOU GENHOUSE BIO CO., LTD. (CN) | 2025-08-14 | — | — | US | disclosed |
| EP-4594304-A2 | IMMUNOSUPPRESSIVE COMPOUNDS | Universität Basel Vizerektorat Forschung (CH) | 2025-08-06 | — | — | EP | disclosed |
| CN-120044110-A | Method for determining lipid chemical structure and ion mobility spectrometry tandem mass spectrometer | 株式会社岛津制作所 | 2025-05-27 | — | — | CN | disclosed |
| CN-119959392-A | Method for identifying unsaturated organic matters and mass spectrum system | 株式会社岛津制作所 | 2025-05-09 | — | — | CN | disclosed |
| CN-115947690-B | Preparation method of indazole molecular building block and application of indazole molecular building block in drug synthesis | 安徽医科大学 | 2025-04-08 | — | — | CN | disclosed |
| CN-119732939-A | Use of Etalocib in preparing medicine for resisting gram positive bacteria infection | 华中科技大学协和深圳医院 | 2025-04-01 | — | — | CN | disclosed |
| WO-2015026792-A1 | ANTIVIRAL COMPOUNDS | ALIOS BIOPHARMA, INC. (US) | 2015-02-26 | — | — | WO | disclosed |
| WO-2014071007-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-08 | — | — | WO | disclosed |
| WO-2014070964-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-08 | — | — | WO | disclosed |
| EP-2227087-B1 | CBI DERIVATIVES SUBJECT TO REDUCTIVE ACTIVATION | SCRIPPS RESEARCH INST (US) | 2013-10-09 | — | — | EP | disclosed |
| US-8377981-B2 | CBI derivatives subject to reductive activation | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-02-19 | — | — | US | disclosed |
| US-20110112163-A1 | CBI DERIVATIVES SUBJECT TO REDUCTIVE ACTIVATION | SCRIPPS RESEARCH INSTITUTE, THE | 2011-05-12 | — | — | US | disclosed |
| EP-2227087-A1 | CBI DERIVATIVES SUBJECT TO REDUCTIVE ACTIVATION | The Scripps Research Institute (US) | 2010-09-15 | — | — | EP | disclosed |
| WO-2009064908-A1 | CBI DERIVATIVES SUBJECT TO REDUCTIVE ACTIVATION | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250257060-A1 | OXADIAZOLE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | HDAC6, HDAC1, HDAC11 | CA1 1837/4885CA2 3037/4885CA9 1747/4885 |
| US-20260102387-A1 | IMMUNOSUPPRESSIVE COMPOUNDS | CHP1, BRD3, IRF3 | CA1 3592/4885CA2 3272/4885CA9 4579/4885 |
| US-20110112163-A1 | CBI DERIVATIVES SUBJECT TO REDUCTIVE ACTIVATION | DBI, CCNI, TDO2 | CA1 657/4885CA2 302/4885CA9 621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.